Black Box Warning GLP-1 receptor agonists, including semaglutide, carry a black box warning for the risk of thyroid C-cell tumors, based on findings in animal studies
Peptide Quality and Risks The use of peptides has become more accepted, partly due to the growth of the GLP-1 community, which has made people more comfortable with injecting themselves, a practice that was previously stigmatized, and this change in perception has occurred over the past five years 2m6s
This is a trust-building scheme
The FDA has not approved these peptides for obesity treatment (FDA guidance on unapproved peptides)
If your blood pressure is not well-controlled before starting the combination, the added variables make management significantly more difficult
Study findings highlight Semaglutide's performance, with the drug inducing a 13.7% decrease in BMI and a 41.7 point reduction in WOMAC scores in case-cohort members